

ASX ANNOUNCEMENT

17 June 2021



CANNTAB UPDATE

Cann Global Limited (ASX:CGB) ("Company" or the "Company") had previously advised the market, most recently in its Quarterly Activities Report released to the market on 29 April, that it expected to receive the shipment of the Canntab order for launch in Australia this quarter.

Joint venture partner Canntab Therapeutics Limited (CSE: PILL.CN) ("Canntab"), has advised that it experienced delays in the final stages of production of its proprietary immediate release cannabidiol formulations.

The Company is pleased to advise however that shipping is imminent for two of the six products ordered. The two products being fulfilled from the order are the CBD 12.5mg and CBD 25mg. The Company looks forward to receiving the remaining four products as soon as Canntab have them ready to ship.

Whilst the delay in receiving the products since the order was placed has been disappointing, this has been outside of Cann Global's control. Cann Global remains excited to be bringing these unique pharmaceutical grade hard pill formulations to the Australian market and is confident that this will underpin future growth in the Company's revenue.

Cann Global continue to work closely with Canntab and will update the market when the products have been received in the country.

The company is progressing towards the launch of its skincare range and is pleased to have recently welcomed new staff with supply chain, sales and marketing expertise. Cann Global will provide a full update in its Quarterly Activities Report and progress on various initiatives in the fourth quarter FY2021 Quarterly Activities and Cashflow Statement released to the market on or before 30 July 2021.

For further information please contact Investor Relations on +61 2 8379 1832, or via email at investorrelations@cannglobal.com.au

ABOUT CANNGLOBAL

Cann Global Limited (ASX:CGB) is a driving force in the hemp and medical Cannabis industries. Our strength comes from our team's core competencies and expertise, and our solid and strategic partnerships with experts in Australia, USA, Israel, Asia, Africa and Canada. We are working under the relevant legislation to ensure that the future in Medical Cannabis and Natural Foods will allow medical practitioners, patients, and consumers to gain access to the right information, as well as the safest, most effective and sustainable products.

AUTHORITY AND CONTACT DETAILS

This announcement has been authorised for release by Sholom Feldman, Managing Director. For further information please contact Investor Relations on +61 (0)2 8379 1832, or via email at investorrelations@cannglobal.com.au.

Level 21, 133 Castlereagh Street,
Sydney NSW 2000 - Australia

Telephone: (02) 8379 1832

investorrelations@cannglobal.com.au
www.cannglobal.com.au